Citadel Advisors’s iRadimed IRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$558K Buy
+5,800
New +$580K ﹤0.01% 9038
2025
Q4
Sell
-5,300
Closed -$377K 13353
2025
Q3
$377K Buy
+5,300
New +$353K ﹤0.01% 9814
2025
Q1
Sell
-900
Closed -$49.5K 15010
2024
Q4
$49.5K Buy
+900
New +$47.4K ﹤0.01% 12402
2024
Q3
Sell
-100
Closed -$4.39K 14717
2024
Q2
$4.39K Sell
100
-1,900
-95% -$80.8K ﹤0.01% 13489
2024
Q1
$88K Buy
2,000
+400
+25% +$17.7K ﹤0.01% 11525
2023
Q4
$76K Buy
+1,600
New +$67.3K ﹤0.01% 11284

Other funds holding IRMD

Citadel Advisors's IRMD Position: Q1 2026 in Review

Citadel Advisors reduced its iRadimed (IRMD) stake by 42% in Q1 2026, selling an estimated $2.33M and leaving 32,504 shares worth $3.13M. The position accounts for ﹤0.01% of the portfolio, ranked #5185.

Citadel Advisors first reported a position in IRMD in Q1 2020 and has held it in 17 quarters since. The position peaked at $5.42M in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • Citadel Advisors held 32,504 shares of iRadimed worth $3.13M as of Q1 2026.
  • Citadel Advisors sold 23,254 iRadimed shares in Q1 2026, an estimated $2.33M.
  • iRadimed made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5185 holding.
  • Citadel Advisors first reported a position in iRadimed in Q1 2020 and has held it in 17 quarters since.
  • Citadel Advisors's iRadimed position peaked at $5.42M in Q4 2025.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.